JP2001519815A - アレルゲン誘発性障害の治療におけるラクトフェリンの使用 - Google Patents
アレルゲン誘発性障害の治療におけるラクトフェリンの使用Info
- Publication number
- JP2001519815A JP2001519815A JP54315498A JP54315498A JP2001519815A JP 2001519815 A JP2001519815 A JP 2001519815A JP 54315498 A JP54315498 A JP 54315498A JP 54315498 A JP54315498 A JP 54315498A JP 2001519815 A JP2001519815 A JP 2001519815A
- Authority
- JP
- Japan
- Prior art keywords
- lactoferrin
- inflammatory
- tnf
- induced
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims description 190
- 229940078795 lactoferrin Drugs 0.000 title claims description 184
- 102000010445 Lactoferrin Human genes 0.000 title claims description 183
- 108010063045 Lactoferrin Proteins 0.000 title claims description 183
- 235000021242 lactoferrin Nutrition 0.000 title claims description 182
- 239000013566 allergen Substances 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title description 52
- 238000000034 method Methods 0.000 claims abstract description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 206010003246 arthritis Diseases 0.000 claims abstract description 17
- 208000006673 asthma Diseases 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 54
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 49
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 49
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 37
- 230000004054 inflammatory process Effects 0.000 claims description 25
- 206010061218 Inflammation Diseases 0.000 claims description 23
- 201000004681 Psoriasis Diseases 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 208000027866 inflammatory disease Diseases 0.000 claims description 19
- 201000004624 Dermatitis Diseases 0.000 claims description 15
- 206010012442 Dermatitis contact Diseases 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000010247 contact dermatitis Diseases 0.000 claims description 11
- 230000028709 inflammatory response Effects 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- 229960001727 tretinoin Drugs 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 4
- 150000001261 hydroxy acids Chemical class 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000003711 photoprotective effect Effects 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 2
- 239000003581 cosmetic carrier Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 13
- 230000007108 local immune response Effects 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 206010040914 Skin reaction Diseases 0.000 abstract description 4
- 230000035483 skin reaction Effects 0.000 abstract description 4
- 231100000430 skin reaction Toxicity 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 3
- 230000000172 allergic effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 67
- 210000004443 dendritic cell Anatomy 0.000 description 47
- 210000001165 lymph node Anatomy 0.000 description 35
- 238000009825 accumulation Methods 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 28
- 210000001821 langerhans cell Anatomy 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 20
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 19
- 210000002510 keratinocyte Anatomy 0.000 description 18
- 230000012292 cell migration Effects 0.000 description 17
- 230000001976 improved effect Effects 0.000 description 17
- 230000028993 immune response Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000000443 aerosol Substances 0.000 description 12
- 210000002615 epidermis Anatomy 0.000 description 12
- 150000003431 steroids Chemical class 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- -1 lactoferrin Nucleic acids Chemical class 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000006433 tumor necrosis factor production Effects 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 7
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 7
- 206010000496 acne Diseases 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 206010042496 Sunburn Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000002029 allergic contact dermatitis Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 231100000053 low toxicity Toxicity 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000798107 Mus musculus Lactotransferrin Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010070835 Skin sensitisation Diseases 0.000 description 3
- 239000000150 Sympathomimetic Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 231100000370 skin sensitisation Toxicity 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 230000001975 sympathomimetic effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 208000035432 Unintended pregnancy Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940042006 metaproterenol sulfate Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 101150008001 pl gene Proteins 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940053470 sodium chloride nasal solution Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 101150035767 trp gene Proteins 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008340 white lotion Substances 0.000 description 1
- 229960001095 xylometazoline hydrochloride Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.医薬有効量のラクトフェリン製品を投与する段階を含んでなるIL-1βの炎 症活性を抑制する方法。 2.(a)局所炎症反応を引き起こす治療用又は化粧用化合物と(b)ラクトフ ェリン製品とを含む組成物。 3.(a)の化合物がトレチノイン、光防護剤及びヒドロキシ酸からなる群より 選択される請求項2記載の組成物。 4.さらに製薬上許容できる担体又は化粧用担体を含む請求項2又は請求項3記 載の組成物。 5.哺乳動物に治療有効量のラクトフェリン製品を投与する段階を含んでなる 、哺乳動物のアレルゲン誘発性炎症性障害を治療する方法。 6.哺乳動物がヒトである請求項5記載の方法。 7.アレルゲン誘発性炎症障害がTNF-αの増加した産生を特徴とする局所免疫 反応を特色とする請求項1、5及び6のいずれかに記載の方法。 8.ラクトフェリン製品が天然に存在するラクトフェリンである請求項1及び5 〜7のいずれかに記載の方法。 9.ラクトフェリン製品が組換え生産されたラクトフェリン又は生物学的に活 性なその類似体である請求項1及び5〜7のいずれかに記載の方法。 10.ラクトフェリン製品がラクトフェリンの生物学的に活性な断片である請求 項1及び5〜7のいずれかに記載の方法。 11.炎症性障害が関節炎と肺炎症性疾患からなる群より選択される請求項1、5 、6、7、8、9及び10のいずれかに記載の方法。 12.炎症性障害が皮膚炎症性障害である請求項1、5、6、7、8、9及び10のいず れかに記載の方法。 13.炎症性障害が接触皮膚炎、乾癬、紫外線誘発性炎症、乳児おむつ皮膚炎及 びアクネからなる群より選択される請求項1、5、6、7、8、9及び10のいずれかに 記載の方法。 14.ラクトフェリン製品がさらにしわとり剤を含む組成物として投与され、炎 症性障害が顔面の皮膚老化である請求項1、5、6、7、8、9及び10のいずれかに記 載の方法。 15.炎症性疾患が喘息である請求項1、5、6、7、8、9及び10のいずれかに記載 の方法。 16.炎症性疾患が副鼻腔炎である請求項1、5、6、7、8、9及び10のいずれかに 記載の方法。 17.炎症性疾患が鼻炎である請求項1、5、6、7、8、9及び10のいずれかに記載 の方法。 18.炎症性疾患が気管支炎である請求項5、6、7、8、9及び10のいずれかに記 載の方法。 19.炎症性疾患が気管支炎である請求項5、6、7、8、9及び10のいずれかに記 載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4189097P | 1997-04-10 | 1997-04-10 | |
US60/041,890 | 1997-04-10 | ||
PCT/US1998/007234 WO1998044940A1 (en) | 1997-04-10 | 1998-04-10 | Use of lactoferin in the treatment of allergen induced disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001519815A true JP2001519815A (ja) | 2001-10-23 |
JP2001519815A5 JP2001519815A5 (ja) | 2005-11-24 |
Family
ID=21918897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54315498A Ceased JP2001519815A (ja) | 1997-04-10 | 1998-04-10 | アレルゲン誘発性障害の治療におけるラクトフェリンの使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20030190303A1 (ja) |
EP (1) | EP0979099B1 (ja) |
JP (1) | JP2001519815A (ja) |
CN (1) | CN1262625A (ja) |
AT (1) | ATE297755T1 (ja) |
AU (1) | AU747385C (ja) |
CA (1) | CA2285960A1 (ja) |
DE (1) | DE69830582T2 (ja) |
ES (1) | ES2245028T3 (ja) |
IL (1) | IL132293A0 (ja) |
NZ (1) | NZ500712A (ja) |
WO (1) | WO1998044940A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501772A (ja) * | 2004-06-11 | 2008-01-24 | シンジェンタ リミテッド | 炎症性皮膚状態を寛解するための方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0980261A4 (en) * | 1997-05-03 | 2003-04-23 | Univ Texas | METHOD FOR PREVENTING AND TREATING A METABOLIC INBALANCE Caused By Insulin In Humans And Other Animals |
US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
NZ519957A (en) * | 2000-01-14 | 2003-08-29 | Meiji Dairies Corp | Antigen-specific IgE antibody production inhibitors |
RU2165769C1 (ru) * | 2000-07-13 | 2001-04-27 | Якубовская Раиса Ивановна | Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения |
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
CA2471766C (en) * | 2001-12-28 | 2011-01-11 | Nrl Pharma, Inc. | Compositions for improving lipid metabolism |
EP2543385A1 (en) | 2002-01-21 | 2013-01-09 | NRL Pharma, Inc. | Novel analgesics |
EP1507554B1 (en) | 2002-05-10 | 2011-08-10 | Agennix Incorporated | Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
WO2003099207A2 (en) * | 2002-05-24 | 2003-12-04 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
ES2358645T3 (es) | 2002-09-16 | 2011-05-12 | Agennix Incorporated | Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética. |
EP1581243A4 (en) * | 2002-12-06 | 2008-01-02 | Agennix Inc | ORAL LACTOFERRINE FOR THE TREATMENT OF SEPSIES |
US7592306B2 (en) | 2002-12-10 | 2009-09-22 | Agennix, Inc. | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
CA2527904A1 (en) * | 2003-06-06 | 2005-05-26 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
US20050075277A1 (en) * | 2003-07-10 | 2005-04-07 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
WO2006098625A1 (en) * | 2005-03-15 | 2006-09-21 | Campina Nederland Holding B.V. | Dermatologic use of milk proteins |
US8178486B2 (en) * | 2005-07-21 | 2012-05-15 | Animal Technology Institute Taiwan | Method for promoting hair growth |
AU2006300009A1 (en) * | 2005-10-14 | 2007-04-19 | Auckland Uniservices Limited | Use of lactoferrin fragments and hydrolysates |
EP1952818A4 (en) * | 2005-10-27 | 2009-10-21 | Sunstar Inc | OSTEOCLASTICIZATION PREPARATION, ORAL AGGREGATION AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST BONE DISEASES WITH LACTOFERRIN-CONTAINING LIPOSOME |
CN103002907A (zh) * | 2010-04-23 | 2013-03-27 | 普若拜特有限公司 | 湿疹治疗 |
CN102370964B (zh) * | 2010-08-16 | 2015-12-09 | 李兴德 | 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用 |
IT201800002457A1 (it) * | 2018-02-07 | 2019-08-07 | Neilos S R L | Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
US20230000975A1 (en) * | 2019-12-11 | 2023-01-05 | N.V. Nutricia | Nutritional composition for improving immune fitness |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
CN115737787B (zh) * | 2022-12-15 | 2024-04-19 | 四川大学 | 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2596986B1 (fr) * | 1986-04-11 | 1988-09-23 | Sederma Sa | Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres |
FR2641696B2 (fr) * | 1986-04-11 | 1991-03-08 | Sederma Sa | Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres |
FR2685202B1 (fr) * | 1991-12-24 | 1995-03-24 | Sederma Sa | Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee. |
JP3184923B2 (ja) * | 1992-01-08 | 2001-07-09 | ビオ セレ ラボラトワール エス ア | 抗リウマチ剤 |
JPH05279266A (ja) * | 1992-04-02 | 1993-10-26 | Imuno Japan:Kk | 歯周病の治療・予防用医薬組成物 |
JP3163171B2 (ja) * | 1992-07-15 | 2001-05-08 | 森永乳業株式会社 | IgA産生促進剤 |
JP3746081B2 (ja) * | 1994-02-24 | 2006-02-15 | 森永乳業株式会社 | 動物皮膚病治療剤 |
JPH0859450A (ja) * | 1994-08-18 | 1996-03-05 | Kose Corp | 皮膚外用剤 |
JP2832517B2 (ja) * | 1994-12-09 | 1998-12-09 | 雪印乳業株式会社 | 大腸菌付着阻止剤 |
JP3911642B2 (ja) * | 1995-06-06 | 2007-05-09 | 株式会社加美乃素本舗 | 皮膚外用剤 |
JP3888707B2 (ja) * | 1996-01-22 | 2007-03-07 | 森永乳業株式会社 | 血管新生病治療剤 |
US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
-
1998
- 1998-04-10 IL IL13229398A patent/IL132293A0/xx not_active IP Right Cessation
- 1998-04-10 AU AU69647/98A patent/AU747385C/en not_active Ceased
- 1998-04-10 AT AT98915471T patent/ATE297755T1/de not_active IP Right Cessation
- 1998-04-10 US US09/058,589 patent/US20030190303A1/en not_active Abandoned
- 1998-04-10 EP EP98915471A patent/EP0979099B1/en not_active Expired - Lifetime
- 1998-04-10 WO PCT/US1998/007234 patent/WO1998044940A1/en active IP Right Grant
- 1998-04-10 DE DE69830582T patent/DE69830582T2/de not_active Expired - Lifetime
- 1998-04-10 ES ES98915471T patent/ES2245028T3/es not_active Expired - Lifetime
- 1998-04-10 CN CN98805584A patent/CN1262625A/zh active Pending
- 1998-04-10 JP JP54315498A patent/JP2001519815A/ja not_active Ceased
- 1998-04-10 CA CA002285960A patent/CA2285960A1/en not_active Abandoned
- 1998-04-10 NZ NZ500712A patent/NZ500712A/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501772A (ja) * | 2004-06-11 | 2008-01-24 | シンジェンタ リミテッド | 炎症性皮膚状態を寛解するための方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1262625A (zh) | 2000-08-09 |
CA2285960A1 (en) | 1998-10-15 |
WO1998044940A1 (en) | 1998-10-15 |
AU747385B2 (en) | 2002-05-16 |
AU6964798A (en) | 1998-10-30 |
EP0979099B1 (en) | 2005-06-15 |
DE69830582D1 (de) | 2005-07-21 |
ES2245028T3 (es) | 2005-12-16 |
ATE297755T1 (de) | 2005-07-15 |
EP0979099A1 (en) | 2000-02-16 |
US20030190303A1 (en) | 2003-10-09 |
NZ500712A (en) | 2002-10-25 |
IL132293A0 (en) | 2001-03-19 |
DE69830582T2 (de) | 2006-05-04 |
AU747385C (en) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001519815A (ja) | アレルゲン誘発性障害の治療におけるラクトフェリンの使用 | |
JP3902406B2 (ja) | 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法 | |
JP2895896B2 (ja) | 脈管狭窄の治療におけるγ―インターフェロンの使用 | |
JP2001519786A (ja) | 創傷治癒用医薬の製造のためのオキシトシン活性を有する物質の使用 | |
CA2907574A1 (en) | Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells | |
JP2021525242A (ja) | 新たな医薬品使用 | |
JP2003518066A (ja) | オリゴ糖を含む組成物、特に化粧品用または皮膚科用組成物、その調製方法、および化粧品処置方法 | |
AU2001275018B2 (en) | Composition and method for enhancing elasticity of tissue | |
JP2014177464A (ja) | Mntfペプチドの美容および皮膚科用製剤 | |
US20050054578A1 (en) | Elastin peptide analogs and uses thereof | |
US7666842B2 (en) | Elastin peptide analogs and uses thereof | |
AU2001275018A1 (en) | Composition and method for enhancing elasticity of tissue | |
JP4689039B2 (ja) | ファゴサイトーシスおよびicam−1発現を調節するための組成物および方法 | |
KR100629546B1 (ko) | 소형 펩타이드 및 천식 및 염증을 치료하기 위한 방법 | |
JP2010527354A (ja) | 免疫調節化合物によるアレルギー性疾患の治療 | |
RU2338553C2 (ru) | Средство для наружного применения, обладающее противовирусной активностью | |
JP2020536065A (ja) | 興奮性神経毒性に関連した損傷の治療用ペプチド組成物 | |
CN114555624A (zh) | 抗炎剂 | |
JP2003509466A (ja) | コルチコトロピン放出ホルモンアナログを使用する異常な細胞増殖の阻害 | |
US6809075B1 (en) | Elastin peptide analogs and uses of same incombination with skin enhancing agents | |
JP6934051B2 (ja) | 皮膚炎症抑制用ペプチドおよびそれを含む皮膚炎症の予防または治療用組成物 | |
MXPA99009240A (en) | Use of lactoferin in the treatment of allergen induced disorders | |
RU2586286C2 (ru) | Применение для лечения и профилактики атеросклероза белково-пептидного комплекса (далее-бпк), полученного из эмбриональной нервной ткани или из быстрозамороженного эмбрионального мозга сельскохозяйственных копытных животных, влияющего на обратный транспорт холестерина из сосудистой стенки и профиль активации моноцитов у пациентов с выраженным атеросклерозом магистральных сосудов или с предрасположенностью к сердечно-сосудистым заболеваниям и способ профилактики и лечения пациентов с атеросклерозом артериальных сосудов и с заболеваниями, вызванными атеросклерозом магистральных и периферических сосудов головного мозга, сердца, сосудов нижних конечностей и аорты (два варианта) | |
KR100756974B1 (ko) | 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트 | |
KR20220164450A (ko) | Agkistrodon piscivorus piscivorus 또는 Naja melanoleuca로부터 유래된 신규한 펩타이드, 및 이를 포함하는 베체트병 또는 류마티스 관절염의 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050407 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050407 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090210 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090512 |